At the Global Think-tank on Steatotic Liver Disease, we launched the People-First Liver Charter
www.nature.com/articles/s41...
+ A call for doubling the diagnostic rate of at-risk MASH
www.thelancet.com/journals/lan...
#SLDthinktank #InMotionTogether #LiverSky
Happy to support and endorse the People First Liver Charter in
โชโช@natmed.nature.comโฌโฌ www.nature.com/articles/s41...
We've always taken a sensitive approach to the language used in our journal, and will continue to do so. See this Editorial www.nature.com/articles/s41...
It was a real pleasure to interview Scott Isaacs and @paulnbrennan.bsky.social regarding their recent paper on 'Anti-diabetic medications in MASLD' in Frontline Gastroenterology - listen below
fgbmj.podbean.com/e/role-of-anti-diabetic-medications-in-the-management-of-masld/
New review in #FG from @paulnbrennan.bsky.social and #scottisaacs - a great summary of the role of antidiabetic medications in MASLD #liversky
fg.bmj.com/content/earl...
The ๐ burden of #MASH is staggering: 5.3% of adults face higher risks of cirrhosis, liver cancer & other complications as fibrosis progresses.
our latest study on MAESTRO-NASH resmetirom data & its real-world implications post-FDA approval www.nature.com/articles/s44... #SLDsummit
Thanks for highlighting our paper @dufourjf.bsky.social! Challenging to undertake these trials in ACLD but hopefully offers some potential utility, more from this cohort to come in our long term follow up analysis this summer ๐ค
Autologous macrophage therapy for cirrhosis: phase 2 open-label randomized controlled trial: During 360-d follow-up, control group developed 4 liver related events, and 3 deaths (2 liver related), whereas no liver-related severe adverse events or deaths occurred in the treatment group.
My take away is that immediately pre- surgery the Post-TIPSS group had worse MELD composites, whilst they had good PSM controlling at time point 6 months before, they were clearly less robust at time of intervention. What about matching with similar non-TIPSS MELD controls at time of op?
The Jan 2025 issue of The Lancet Gastroenterology & Hepatology is out today at www.thelancet.com/gastrohep!
Content includes UPFs, Crohnโs disease, rectal cancer, coeliac disease, MASLD + heart disease, gastroparesis + moreโฆ
#GastroSky #LiverSky #MedSky
